NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome‐dependent degradation of ISGylated p53
Cancer Science · 2023-09 · 114 (9) · 3523-3536
DOI: 10.1111/cas.15887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 22.06.2023. Verfasst von Yonggang Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cooperation Project of Nanchong Science and Technology, National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Nuclear factor erythroid 2‐like 3 (NFE2L3) is a member of the cap ‘n’ collar basic‐region leucine zipper (CNC‐bZIP) transcription factor family that plays a vital role in modulating oxidation–reduction steady‐state and proteolysis. Accumulating evidence suggests that NFE2L3 participates in cancer development; however, little is known about the mechanism by which NFE2L3 regulates hepatocellular carcinoma (HCC) cell growth. Here, we confirmed that NFE2L3 promotes HCC cell proliferation by acting as a transcription factor, which directly induces the expression of proteasome and interferon‐stimulated gene 15 (ISG15) to enhance the proteasome‐dependent degradation of ISGylated p53. Post‐translational ISGylation abated the stability of p53 and facilitated HCC cell growth. In summary, we uncovered the pivotal role of NFE2L3 in promoting HCC cell proliferation during proteostasis. This finding may provide a new target for the clinical treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China.
- Research Center of Clinical Medical Sciences, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shen…
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
- Shenzhen Luohu Hospital Group, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
ORCID-Profile: Yonggang Ren, Aifa Tang
Förderung
- Cooperation Project of Nanchong Science and Technology
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
- Research Development Fund of North Sichuan Medical College
- Shenzhen Science and Technology Innovation Commission
- Youth Scientific Research Project of Sichuan Medical Association
Zitieren
APA
Ren, Y., Yang, J., Ding, Z., Zheng, M., Qiu, L., Tang, A., & Huang, D. (2023). NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome‐dependent degradation of ISGylated p53. Cancer Science, 114(9), 3523-3536. https://doi.org/10.1111/cas.15887
Vancouver
Ren Y, Yang J, Ding Z, Zheng M, Qiu L, Tang A, et al. NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome‐dependent degradation of ISGylated p53. Cancer Science. 2023;114(9):3523-3536. doi:10.1111/cas.15887
BibTeX
@article{Ren2023,
author = {Ren, Yonggang and Yang, Jing and Ding, Zhiran and Zheng, Menghua and Qiu, Lu and Tang, Aifa and Huang, Dandan},
title = {NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome‐dependent degradation of ISGylated p53},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {9},
pages = {3523--3536},
doi = {10.1111/cas.15887}
}
EUVIMED